[HTML][HTML] A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

ME Weinblatt, JM Kremer, AD Bankhurst… - … England Journal of …, 1999 - Mass Medical Soc
Background Patients treated with methotrexate for rheumatoid arthritis often improve but
continue to have active disease. This study was undertaken to determine whether the addition …

2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis

…, KK Huston, G Kerr, J Kremer… - Arthritis & …, 2021 - Wiley Online Library
Objective To develop updated guidelines for the pharmacologic management of rheumatoid
arthritis. Methods We developed clinically relevant population, intervention, comparator, …

Genetics of rheumatoid arthritis contributes to biology and drug discovery

…, RJ Carroll, AE Eyler, JD Greenberg, JM Kremer… - Nature, 2014 - nature.com
A major challenge in human genetics is to devise a systematic strategy to integrate disease-associated
variants with diverse genomic and biological data sets to provide insight into …

[PDF][PDF] 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the …

…, JR Curtis, AF Kavanaugh, JM Kremer… - Arthritis care & …, 2012 - Wiley Online Library
The American College of Rheumatology (ACR) most recently published recommendations
for the use of diseasemodifying antirheumatic drugs (DMARDs) and biologic agents in the …

[HTML][HTML] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition

…, M Schiff, M Luggen, Y Sherrer, J Kremer… - … England Journal of …, 2005 - Mass Medical Soc
Background A substantial number of patients with rheumatoid arthritis have an inadequate
or unsustained response to tumor necrosis factor α (TNF-α) inhibitors. We conducted a …

[HTML][HTML] Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

JM Kremer, R Westhovens, M Leon… - … England Journal of …, 2003 - Mass Medical Soc
Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role in …

[HTML][HTML] Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

R Fleischmann, J Kremer, J Cush… - … England Journal of …, 2012 - Mass Medical Soc
Background Tofacitinib (CP-690,550) is a novel oral Janus kinase inhibitor that is being
investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid …

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial

JM Kremer, HK Genant, LW Moreland… - Annals of internal …, 2006 - acpjournals.org
Background: The selective co-stimulation modulator abatacept demonstrated efficacy for
treating rheumatoid arthritis in early clinical studies. Objective: To evaluate the effects of …

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin‐1 receptor antagonist, in combination with methotrexate: results of a twenty‐four …

…, ME Weinblatt, LW Moreland, J Kremer… - Arthritis & …, 2002 - Wiley Online Library
Objective To evaluate the efficacy and safety of anakinra in combination with methotrexate (MTX)
in patients with active rheumatoid arthritis (RA). Methods Patients with moderate‐to‐…

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase IIb, double‐blind, randomized, placebo …

JM Kremer, M Dougados, P Emery… - … : Official Journal of …, 2005 - Wiley Online Library
Objective To determine the clinical efficacy, safety, and immunogenicity of abatacept (CTLA‐4Ig),
a selective costimulation modulator, in patients with rheumatoid arthritis (RA) that has …